= 0.60). In one of the longest follow-up cohorts of children with CML reported to date, imatinib resulted in growth deceleration, particularly when initiated before the onset of pubertal growth spurt. Despite catch-up growth during adolescence, final height z-scores remained reduced at skeletal maturity.
Sadanand et al. (Mon,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: